Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid Tumors.

Lutzmann M, Bernex F, da Costa de Jesus C, Hodroj D, Marty C, Plo I, Vainchenker W, Tosolini M, Forichon L, Bret C, Queille S, Marchive C, Hoffmann JS, Méchali M.

Cell Rep. 2019 Sep 10;28(11):2851-2865.e4. doi: 10.1016/j.celrep.2019.07.095.

2.

Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development.

Balligand T, Achouri Y, Pecquet C, Gaudray G, Colau D, Hug E, Rahmani Y, Stroobant V, Plo I, Vainchenker W, Kralovics R, Van den Eynde BJ, Defour JP, Constantinescu SN.

Leukemia. 2019 Aug 30. doi: 10.1038/s41375-019-0538-1. [Epub ahead of print]

PMID:
31471561
3.

The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications.

Vainchenker W, Plo I, Marty C, Varghese LN, Constantinescu SN.

Expert Rev Hematol. 2019 Jun;12(6):437-448. doi: 10.1080/17474086.2019.1617129. Epub 2019 May 22.

PMID:
31092065
4.

"Mixed" Myeloproliferative Neoplasm Due to Co-Occurrence of Different Driver Mutations.

Plo I.

Acta Haematol. 2019;141(4):268-270. doi: 10.1159/000498979. Epub 2019 Apr 18. No abstract available.

5.

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.

Pecquet C, Chachoua I, Roy A, Balligand T, Vertenoeil G, Leroy E, Albu RI, Defour JP, Nivarthi H, Hug E, Xu E, Ould-Amer Y, Mouton C, Colau D, Vertommen D, Shwe MM, Marty C, Plo I, Vainchenker W, Kralovics R, Constantinescu SN.

Blood. 2019 Jun 20;133(25):2669-2681. doi: 10.1182/blood-2018-09-874578. Epub 2019 Mar 22.

PMID:
30902807
6.

Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.

Toppaldoddi KR, da Costa Cacemiro M, Bluteau O, Panneau-Schmaltz B, Pioch A, Muller D, Villeval JL, Raslova H, Constantinescu SN, Plo I, Vainchenker W, Marty C.

Oncogene. 2019 Mar;38(10):1651-1660. doi: 10.1038/s41388-018-0538-z. Epub 2018 Oct 19.

PMID:
30846848
7.

Disrupted filamin A/αIIbβ3 interaction induces macrothrombocytopenia by increasing RhoA activity.

Donada A, Balayn N, Sliwa D, Lordier L, Ceglia V, Baschieri F, Goizet C, Favier R, Tosca L, Tachdjian G, Denis CV, Plo I, Vainchenker W, Debili N, Rosa JP, Bryckaert M, Raslova H.

Blood. 2019 Apr 18;133(16):1778-1788. doi: 10.1182/blood-2018-07-861427. Epub 2019 Jan 2.

8.

Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome.

Bellanné-Chantelot C, Schmaltz-Panneau B, Marty C, Fenneteau O, Callebaut I, Clauin S, Docet A, Damaj GL, Leblanc T, Pellier I, Stoven C, Souquere S, Antony-Debré I, Beaupain B, Aladjidi N, Barlogis V, Bauduer F, Bensaid P, Boespflug-Tanguy O, Berger C, Bertrand Y, Carausu L, Fieschi C, Galambrun C, Schmidt A, Journel H, Mazingue F, Nelken B, Quah TC, Oksenhendler E, Ouachée M, Pasquet M, Saada V, Suarez F, Pierron G, Vainchenker W, Plo I, Donadieu J.

Blood. 2018 Sep 20;132(12):1318-1331. doi: 10.1182/blood-2017-12-820308. Epub 2018 Jun 18.

9.

HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis.

Sevin M, Kubovcakova L, Pernet N, Causse S, Vitte F, Villeval JL, Lacout C, Cordonnier M, Rodrigues-Lima F, Chanteloup G, Mosca M, Chrétien ML, Bastie JN, Audia S, Sagot P, Ramla S, Martin L, Gleave M, Mezger V, Skoda R, Plo I, Garrido C, Girodon F, de Thonel A.

Nat Commun. 2018 Apr 12;9(1):1431. doi: 10.1038/s41467-018-03627-9.

10.

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.

Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN.

F1000Res. 2018 Jan 17;7:82. doi: 10.12688/f1000research.13167.1. eCollection 2018. Review.

11.

New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis.

Pasquier F, Marty C, Balligand T, Verdier F, Grosjean S, Gryshkova V, Raslova H, Constantinescu SN, Casadevall N, Vainchenker W, Bellanné-Chantelot C, Plo I.

Haematologica. 2018 Apr;103(4):575-586. doi: 10.3324/haematol.2017.176370. Epub 2017 Dec 21.

12.

Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect.

Messaoudi K, Ali A, Ishaq R, Palazzo A, Sliwa D, Bluteau O, Souquère S, Muller D, Diop KM, Rameau P, Lapierre V, Marolleau JP, Matthias P, Godin I, Pierron G, Thomas SG, Watson SP, Droin N, Vainchenker W, Plo I, Raslova H, Debili N.

Nat Commun. 2017 Nov 27;8(1):1786. doi: 10.1038/s41467-017-01690-2.

13.

Identification of MPL R102P Mutation in Hereditary Thrombocytosis.

Bellanné-Chantelot C, Mosca M, Marty C, Favier R, Vainchenker W, Plo I.

Front Endocrinol (Lausanne). 2017 Sep 20;8:235. doi: 10.3389/fendo.2017.00235. eCollection 2017.

14.

Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.

Plo I, Bellanné-Chantelot C, Mosca M, Mazzi S, Marty C, Vainchenker W.

Front Endocrinol (Lausanne). 2017 Sep 12;8:234. doi: 10.3389/fendo.2017.00234. eCollection 2017. Review.

15.

Quantitative Proteome Heterogeneity in Myeloproliferative Neoplasm Subtypes and Association with JAK2 Mutation Status.

Socoro-Yuste N, Čokić VP, Mondet J, Plo I, Mossuz P.

Mol Cancer Res. 2017 Jul;15(7):852-861. doi: 10.1158/1541-7786.MCR-16-0495. Epub 2017 Mar 17.

16.

Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.

Gilles L, Arslan AD, Marinaccio C, Wen QJ, Arya P, McNulty M, Yang Q, Zhao JC, Konstantinoff K, Lasho T, Pardanani A, Stein B, Plo I, Sundaravel S, Wickrema A, Migliaccio A, Gurbuxani S, Vainchenker W, Platanias LC, Tefferi A, Crispino JD.

J Clin Invest. 2017 Apr 3;127(4):1316-1320. doi: 10.1172/JCI82905. Epub 2017 Feb 27.

17.

P53 deletion and NrasG12D cooperate for AML.

Vainchenker W, Plo I.

Blood. 2017 Jan 19;129(3):271-273. doi: 10.1182/blood-2016-11-750547. No abstract available.

PMID:
28104674
18.

An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L.

Favale F, Messaoudi K, Varghese LN, Boukour S, Pecquet C, Gryshkova V, Defour JP, Albu RI, Bluteau O, Ballerini P, Leverger G, Plo I, Debili N, Raslova H, Favier R, Constantinescu SN, Vainchenker W.

Blood. 2016 Dec 29;128(26):3146-3158. doi: 10.1182/blood-2016-06-722058. Epub 2016 Nov 10.

PMID:
28034873
19.

A driver role for GABA metabolism in controlling stem and proliferative cell state through GHB production in glioma.

El-Habr EA, Dubois LG, Burel-Vandenbos F, Bogeas A, Lipecka J, Turchi L, Lejeune FX, Coehlo PL, Yamaki T, Wittmann BM, Fareh M, Mahfoudhi E, Janin M, Narayanan A, Morvan-Dubois G, Schmitt C, Verreault M, Oliver L, Sharif A, Pallud J, Devaux B, Puget S, Korkolopoulou P, Varlet P, Ottolenghi C, Plo I, Moura-Neto V, Virolle T, Chneiweiss H, Junier MP.

Acta Neuropathol. 2017 Apr;133(4):645-660. doi: 10.1007/s00401-016-1659-5. Epub 2016 Dec 28.

20.

Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0.

Manchev VT, Bouzid H, Antony-Debré I, Leite B, Meurice G, Droin N, Prebet T, Costello RT, Vainchenker W, Plo I, Diop M, Macintyre E, Asnafi V, Favier R, Baccini V, Raslova H.

J Cell Mol Med. 2017 Jun;21(6):1237-1242. doi: 10.1111/jcmm.13051. Epub 2016 Dec 20.

21.

Eltrombopag, a potent stimulator of megakaryopoiesis.

Raslova H, Vainchenker W, Plo I.

Haematologica. 2016 Dec;101(12):1443-1445. No abstract available.

22.

CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress.

Zhang Y, Dépond M, He L, Foudi A, Kwarteng EO, Lauret E, Plo I, Desterke C, Dessen P, Fujii N, Opolon P, Herault O, Solary E, Vainchenker W, Joulin V, Louache F, Wittner M.

Sci Rep. 2016 Nov 25;6:37827. doi: 10.1038/srep37827.

23.

Ph(-) myeloproliferative neoplasm red blood cells display deregulation of IQGAP1-Rho GTPase signaling depending on CALR/JAK2 status.

Socoro-Yuste N, Dagher MC, Gonzalez De Peredo A, Mondet J, Zaccaria A, Roux Dalvai F, Plo I, Cahn JY, Mossuz P.

Biochim Biophys Acta. 2016 Nov;1863(11):2758-2765. doi: 10.1016/j.bbamcr.2016.08.012. Epub 2016 Aug 24.

24.

Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint.

Roy A, Lordier L, Pioche-Durieu C, Souquere S, Roy L, Rameau P, Lapierre V, Le Cam E, Plo I, Debili N, Raslova H, Vainchenker W.

Haematologica. 2016 Dec;101(12):1469-1478. Epub 2016 Aug 11.

25.

Aspects biologiques de la voie JAK/STAT dans les néoplasmes myéloprolifératifs classiques négatifs pour BCR-ABL.

Mosca M, Vertenoeil G, Toppaldoddi KR, Plo I, Vainchenker W.

Bull Cancer. 2016 Jun;103(6 Suppl 1):S16-28. doi: 10.1016/S0007-4551(16)30142-4. Review. French.

PMID:
27494969
26.

CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner.

Abdelouahab H, Zhang Y, Wittner M, Oishi S, Fujii N, Besancenot R, Plo I, Ribrag V, Solary E, Vainchenker W, Barosi G, Louache F.

Oncotarget. 2016 Jul 22;8(33):54082-54095. doi: 10.18632/oncotarget.10789. eCollection 2017 Aug 15.

27.

EZH2: a molecular switch of the MPN phenotype.

Vainchenker W, Plo I.

Blood. 2016 Jun 30;127(26):3297-8. doi: 10.1182/blood-2016-04-711770. No abstract available.

PMID:
27365409
28.

ATG2B and GSKIP: 2 new genes predisposing to myeloid malignancies.

Plo I, Bellanné-Chantelot C, Vainchenker W.

Mol Cell Oncol. 2015 Oct 29;3(2):e1094564. doi: 10.1080/23723556.2015.1094564. eCollection 2016 Mar.

29.

TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis.

Mahfoudhi E, Talhaoui I, Cabagnols X, Della Valle V, Secardin L, Rameau P, Bernard OA, Ishchenko AA, Abbes S, Vainchenker W, Saparbaev M, Plo I.

DNA Repair (Amst). 2016 Jul;43:78-88. doi: 10.1016/j.dnarep.2016.05.031. Epub 2016 May 24.

PMID:
27289557
30.

Recent advances in understanding myelofibrosis and essential thrombocythemia.

Vainchenker W, Constantinescu SN, Plo I.

F1000Res. 2016 Apr 19;5. pii: F1000 Faculty Rev-700. doi: 10.12688/f1000research.8081.1. eCollection 2016. Review.

31.

Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin.

Balligand T, Achouri Y, Pecquet C, Chachoua I, Nivarthi H, Marty C, Vainchenker W, Plo I, Kralovics R, Constantinescu SN.

Leukemia. 2016 Aug;30(8):1775-8. doi: 10.1038/leu.2016.47. Epub 2016 Feb 29. No abstract available.

PMID:
26987905
32.

P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis.

Mahfoudhi E, Lordier L, Marty C, Pan J, Roy A, Roy L, Rameau P, Abbes S, Debili N, Raslova H, Chang Y, Debussche L, Vainchenker W, Plo I.

Oncotarget. 2016 May 31;7(22):31980-92. doi: 10.18632/oncotarget.7881.

33.

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.

Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu RI, Marty C, Gryshkova V, Defour JP, Vertenoeil G, Ngo A, Koay A, Raslova H, Courtoy PJ, Choong ML, Plo I, Vainchenker W, Kralovics R, Constantinescu SN.

Blood. 2016 Mar 10;127(10):1325-35. doi: 10.1182/blood-2015-11-681932. Epub 2015 Dec 14.

PMID:
26668133
34.

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.

Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M, Villeval JL, Raslova H, Kralovics R, Constantinescu SN, Plo I, Vainchenker W.

Blood. 2016 Mar 10;127(10):1317-24. doi: 10.1182/blood-2015-11-679571. Epub 2015 Nov 25.

PMID:
26608331
35.

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.

Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC, Marzac C, Le Couédic JP, Droin N, Chachoua I, Favier R, Diop MK, Ugo V, Casadevall N, Debili N, Raslova H, Bellanné-Chantelot C, Constantinescu SN, Bluteau O, Plo I, Vainchenker W.

Blood. 2016 Jan 21;127(3):333-42. doi: 10.1182/blood-2015-07-661983. Epub 2015 Oct 8.

PMID:
26450985
36.

Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies.

Saliba J, Saint-Martin C, Di Stefano A, Lenglet G, Marty C, Keren B, Pasquier F, Valle VD, Secardin L, Leroy G, Mahfoudhi E, Grosjean S, Droin N, Diop M, Dessen P, Charrier S, Palazzo A, Merlevede J, Meniane JC, Delaunay-Darivon C, Fuseau P, Isnard F, Casadevall N, Solary E, Debili N, Bernard OA, Raslova H, Najman A, Vainchenker W, Bellanné-Chantelot C, Plo I.

Nat Genet. 2015 Oct;47(10):1131-40. doi: 10.1038/ng.3380. Epub 2015 Aug 17.

PMID:
26280900
37.

[Properties and biological roles of TET proteins during embryogenesis and in hematopoiesis].

Mahfoudhi E, Secardin L, Scourzic L, Bernard O, Vainchenker W, Plo I.

Med Sci (Paris). 2015 Mar;31(3):268-74. doi: 10.1051/medsci/20153103012. Epub 2015 Apr 8. Review. French.

38.

Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands.

Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabionar H, Wehrman TS, Krutzik P, Demharter S, Plo I, Weissman IL, Minary P, Majeti R, Constantinescu SN, Piehler J, Garcia KC.

Cell. 2015 Mar 12;160(6):1196-208. doi: 10.1016/j.cell.2015.02.011. Epub 2015 Feb 26.

39.

TET2 loss, a rescue of JAK2V617F HSCs.

Vainchenker W, Plo I.

Blood. 2015 Jan 8;125(2):212-3. doi: 10.1182/blood-2014-10-606624.

PMID:
25573967
40.

Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia.

Antony-Debré I, Manchev VT, Balayn N, Bluteau D, Tomowiak C, Legrand C, Langlois T, Bawa O, Tosca L, Tachdjian G, Leheup B, Debili N, Plo I, Mills JA, French DL, Weiss MJ, Solary E, Favier R, Vainchenker W, Raslova H.

Blood. 2015 Feb 5;125(6):930-40. doi: 10.1182/blood-2014-06-585513. Epub 2014 Dec 9.

41.

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.

Pasquier F, Cabagnols X, Secardin L, Plo I, Vainchenker W.

Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S23-35. doi: 10.1016/j.clml.2014.06.014. Review.

PMID:
25486952
42.

p19 INK4d controls hematopoietic stem cells in a cell-autonomous manner during genotoxic stress and through the microenvironment during aging.

Hilpert M, Legrand C, Bluteau D, Balayn N, Betems A, Bluteau O, Villeval JL, Louache F, Gonin P, Debili N, Plo I, Vainchenker W, Gilles L, Raslova H.

Stem Cell Reports. 2014 Dec 9;3(6):1085-102. doi: 10.1016/j.stemcr.2014.10.005. Epub 2014 Nov 20.

43.

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.

Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, Girodon F, Alexandre JH, Mansier O, Viallard JF, Lippert E, Murati A, Mozziconacci MJ, Saussoy P, Vekemans MC, Knoops L, Pasquier F, Ribrag V, Solary E, Plo I, Constantinescu SN, Casadevall N, Vainchenker W, Marzac C, Bluteau O.

Leukemia. 2015 Jan;29(1):249-52. doi: 10.1038/leu.2014.270. Epub 2014 Sep 12. No abstract available.

PMID:
25212275
44.

p53 at the crossroads of MPN treatment.

Plo I.

Blood. 2014 Jul 31;124(5):668-9. doi: 10.1182/blood-2014-06-579623.

45.

TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells.

Langlois T, da Costa Reis Monte-Mor B, Lenglet G, Droin N, Marty C, Le Couédic JP, Almire C, Auger N, Mercher T, Delhommeau F, Christensen J, Helin K, Debili N, Fuks F, Bernard OA, Solary E, Vainchenker W, Plo I.

Stem Cells. 2014 Aug;32(8):2084-97. doi: 10.1002/stem.1718.

46.

DNA binding of the p21 repressor ZBTB2 is inhibited by cytosine hydroxymethylation.

Lafaye C, Barbier E, Miscioscia A, Saint-Pierre C, Kraut A, Couté Y, Plo I, Gasparutto D, Ravanat JL, Breton J.

Biochem Biophys Res Commun. 2014 Mar 28;446(1):341-6. doi: 10.1016/j.bbrc.2014.02.122. Epub 2014 Mar 4.

PMID:
24607898
47.

Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone.

Yamada O, Mahfoudhi E, Plo I, Ozaki K, Nakatake M, Akiyama M, Yamada H, Kawauchi K, Vainchenker W.

J Clin Oncol. 2014 Jul 20;32(21):e76-9. doi: 10.1200/JCO.2012.47.8669. Epub 2014 Feb 10. No abstract available.

PMID:
24516035
48.

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.

Marty C, Saint-Martin C, Pecquet C, Grosjean S, Saliba J, Mouton C, Leroy E, Harutyunyan AS, Abgrall JF, Favier R, Toussaint A, Solary E, Kralovics R, Constantinescu SN, Najman A, Vainchenker W, Plo I, Bellanné-Chantelot C.

Blood. 2014 Feb 27;123(9):1372-83. doi: 10.1182/blood-2013-05-504555. Epub 2014 Jan 7.

PMID:
24398328
49.

Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

Hasan S, Cassinat B, Droin N, Le Couedic JP, Favale F, Monte-Mor B, Lacout C, Fontenay M, Dosquet C, Chomienne C, Solary E, Villeval JL, Casadevall N, Kiladjian JJ, Vainchenker W, Plo I.

Leukemia. 2014 Feb;28(2):460-3. doi: 10.1038/leu.2013.303. Epub 2013 Oct 22. No abstract available.

PMID:
24150219
50.

Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients.

Saliba J, Hamidi S, Lenglet G, Langlois T, Yin J, Cabagnols X, Secardin L, Legrand C, Galy A, Opolon P, Benyahia B, Solary E, Bernard OA, Chen L, Debili N, Raslova H, Norol F, Vainchenker W, Plo I, Di Stefano A.

PLoS One. 2013 Sep 16;8(9):e74257. doi: 10.1371/journal.pone.0074257. eCollection 2013.

Supplemental Content

Support Center